United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp Chief Financial Officer and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. On May 4, 2026, he exercised stock options to acquire 10,000 shares of common stock at a strike price of $135.42 per share and sold 10,000 shares in multiple open-market trades at prices generally between the high $560s and low $580s per share. The filing states these trades were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025, indicating the timing was scheduled in advance. After the transactions, Edgemond continues to hold 18,876 shares of common stock directly, along with 32,500 stock options, signaling he retains a meaningful equity stake in UNITED THERAPEUTICS.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at $146.03 per share and sold 9,500 shares in open-market trades on May 1, 2026. The sales occurred at prices around $565.78–$571.95 per share in multiple transactions.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until up to 1,734,410 options are exercised or until December 31, 2026. Following the transactions, Rothblatt holds 40,513 shares directly, plus additional indirect holdings through family trusts and a spouse account.
Reported sale of company stock under Rule 144 and a 10b5-1 plan. The filing shows 148,750 shares tied to an exercise of stock options dated 05/04/2026, with multiple prior 10b5-1 sales by James C. Edgemond of 10,000 shares per trade on several dates in March–April 2026 and proceeds listed for each trade.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options and sold shares in a pre-planned transaction. On April 30, 2026, she exercised 9,500 stock options at $146.03 per share and sold 9,500 shares of common stock in open-market trades at prices such as $579.51 and $570.76 per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the transactions, Rothblatt holds 50,013 common shares directly and also has indirect ownership through family trusts and a spouse account, including 324,443 shares, 258,117 shares, 45,596 shares, 10,962 shares held by trusts, and 166 shares held by her spouse.
UNITED THERAPEUTICS Corp CFO James Edgemond exercised and sold shares in a planned transaction. On April 30, 2026, he exercised 10,000 stock options for Common Stock at a strike price of $135.42 per share and then sold 10,000 shares in a series of open-market trades at prices reported between $569.24 and $578.76 per share.
These actions were made under a Rule 10b5-1 trading plan entered into on October 31, 2025. After the transactions, he directly owned 18,876 shares of United Therapeutics common stock.
Martine Rothblatt filed a Form 144 to sell 190,000 shares of common stock on 05/01/2026. The filing lists the method as an Exercise of Stock Options with cash proceeds and shows an aggregate figure of $108,556,500.00. The broker listed is Morgan Stanley Smith Barney LLC (New York).
The filing also enumerates multiple 10b5-1 sales of 9,500 shares on many dates in March–April 2026 and a separate 75-share sale on 03/13/2026. These prior sale entries show per-trade proceeds in the filing (examples include $5,430,339.25, $5,561,056.15, $40,271.25).
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at $146.03 per share and sold 9,500 common shares in multiple open-market trades at prices ranging from about $565.10 to $574.31. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising up to 1,734,410 options expiring in March 2027 or December 31, 2026. After these transactions, she holds 50,013 common shares directly, additional common shares indirectly through various family trusts and her spouse, and 91,288 stock options remain outstanding.
Vanguard Capital Management reported beneficial ownership of 2,278,348 shares of United Therapeutics Corporation Common Stock, representing 5.19% of the class as of 03/31/2026. The filing shows Vanguard has sole voting power over 320,809 shares and sole dispositive power over 2,278,348 shares. The filing states these holdings include securities managed across Vanguard affiliates and funds.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at $146.03 per share and, on the same day, sold 9,500 shares in multiple open-market transactions around $565–$572 per share.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the trades, Rothblatt directly owns 40,513 common shares and also has additional indirect holdings through family trusts and a spouse account.